Clincosm LogoSign in Get a demo

Melanoma

Showing 51 - 75 of 1,172
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, Non-small Cell Carcinoma, Histiocytic Tumor Trial (BDTX-4933)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +32 more
  • (no location specified)
Mar 30, 2023

Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer Trial (HFB200603, Tislelizumab)

Not yet recruiting
  • Renal Cell Carcinoma
  • +4 more
  • (no location specified)
Mar 15, 2023

Solid Tumor, Haematological Malignancy, Malignancy Trial in United Kingdom (Entrectinib)

Recruiting
  • Solid Tumor
  • +10 more
  • Belfast, United Kingdom
  • +25 more
Mar 14, 2023

Malignancy, Malignant Tumor, Lymphoproliferative Disorders Trial in United Kingdom (Atezolizumab)

Not yet recruiting
  • Malignancy
  • +8 more
  • Belfast, United Kingdom
  • +25 more
Mar 14, 2023

Solid Tumor, Haematological Malignancy, Melanoma Trial in United Kingdom (Vemurafenib, Cobimetinib)

Recruiting
  • Solid Tumor
  • +11 more
  • Belfast, United Kingdom
  • +16 more
Mar 2, 2023

Melanoma, Malignant Melanoma Trial (T3011 + Cobimetinib)

Not yet recruiting
  • Melanoma
  • Malignant Melanoma
  • T3011 + Cobimetinib
  • (no location specified)
Mar 3, 2023

Ovarian Cancer, Melanoma, Triple Negative Breast Cancer Trial (NM1F Injection, Pembrolizumab injection)

Not yet recruiting
  • Ovarian Cancer
  • +3 more
  • NM1F Injection
  • Pembrolizumab injection
  • (no location specified)
Feb 23, 2023

Melanoma, Renal Cell Carcinoma Trial in Hull (Zirconium 89Zr crefmirlimab berdoxam)

Recruiting
  • Melanoma
  • Renal Cell Carcinoma
  • Zirconium 89Zr crefmirlimab berdoxam
  • Hull, United Kingdom
    Castle Hill Hospital
Feb 15, 2023

Analysis of Circulating Exosomes in Melanoma Patients

Active, not recruiting
  • Melanoma
    • Besançon, France
      CHU de Besançon
    Feb 23, 2023

    Profiling of Pembrolizumab and Nivolumab in Melanoma and/or

    Active, not recruiting
    • Lung Non-Small Cell Carcinoma
    • Melanoma
    • Biospecimen Collection
    • +2 more
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Feb 13, 2023

    Melanoma, Non Small Cell Lung Cancer Trial in Moscow, Omsk, Saint Petersburg (BCD-201, Keytruda)

    Active, not recruiting
    • Melanoma
    • Non Small Cell Lung Cancer
    • Moscow, Russian Federation
    • +2 more
    Feb 13, 2023

    Melanoma Recurrence With Circulating Tumor DNA (ctDNA)

    Active, not recruiting
    • Melanoma
      • Murray, Utah
      • +1 more
      Feb 17, 2023

      Melanoma, Melanoma (Skin), Melanoma Stage III Trial in Belarus, India, Russian Federation (BCD-217, BCD-100, Placebo)

      Recruiting
      • Melanoma
      • +6 more
      • BCD-217
      • +2 more
      • Babruysk, Belarus
      • +62 more
      Feb 8, 2023

      Metastatic Melanoma, Unresectable Melanoma, Melanoma Trial (Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover

      Not yet recruiting
      • Metastatic Melanoma
      • +2 more
      • Lifileucel plus Pembrolizumab
      • Pembrolizumab with Optional Crossover Period
      • (no location specified)
      Feb 13, 2023

      Melanoma Trial in Beijing (KD6001, Toripalimab)

      Not yet recruiting
      • Melanoma
      • Beijing, China
        Beijing Cancer Hospital
      Feb 3, 2023

      Advanced Cancer, Advanced Solid Tumor, Tumor Malignant Trial in United Kingdom (Fosifloxuridine Nafalbenamide, Leucovorin,

      Not yet recruiting
      • Advanced Cancer
      • +16 more
      • Fosifloxuridine Nafalbenamide
      • +3 more
      • Birmingham, United Kingdom
      • +3 more
      Feb 1, 2023

      Adverse Events-related Healthcare Resource Utilization and Costs

      Completed
      • Melanoma
      • East Hanover, New Jersey
        Novartis Pharmaceuticals
      Jan 27, 2023

      Cancer, Solid Tumor, Melanoma Trial (KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose

      Not yet recruiting
      • Cancer
      • +16 more
      • KVA12123 - Dose Escalation
      • +3 more
      • (no location specified)
      Feb 2, 2023

      Prospective Procurement of Tumor Tissue to Identify Novel

      Enrolling by invitation
      • Solid Tumors
      • +7 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Feb 2, 2023

        Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ) Trial in Worldwide (Autologous genetically modified

        Recruiting
        • Endometrial Cancer
        • +8 more
        • Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
        • Orlando, Florida
        • +21 more
        Feb 2, 2023

        Melanoma Trial in Philadelphia (Mature dendritic cell (DC) vaccine, Cyclophosphamide 300mg/m^2, Pembrolizumab)

        Active, not recruiting
        • Melanoma
        • Mature dendritic cell (DC) vaccine
        • +2 more
        • Philadelphia, Pennsylvania
          University of Pennsylvania
        Feb 2, 2023

        NSCLC, Melanoma Trial (IMM60, Pembrolizumab)

        Not yet recruiting
        • Non-small Cell Lung Cancer
        • Melanoma
        • (no location specified)
        Jan 24, 2023

        Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease

        Active, not recruiting
        • Melanoma
        • +4 more
          • Bethesda, Maryland
            National Institutes of Health Clinical Center
          Jan 31, 2023

          Melanoma Trial in Worldwide (Nivolumab, Relatlimab)

          Recruiting
          • Melanoma
          • Phoenix, Arizona
          • +84 more
          Jan 31, 2023

          Cancer, Tumor, Solid, Advanced Solid Tumor Trial in Brussels, Barcelona, Madrid (JK08)

          Recruiting
          • Cancer
          • +6 more
          • Brussels, Belgium
          • +3 more
          Jan 30, 2023